Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-117426
Filing Date
2024-10-25
Accepted
2024-10-25 16:16:15
Documents
2
Period of Report
2024-10-15

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 13257
2 EX-24.DOCX achv-ex24_docx.htm EX-24.DOCX 12724
  Complete submission text file 0000950170-24-117426.txt   27635
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 22722 29TH DR SE SUITE 100 BOTHELL WA 98021
Business Address
Xinos Jaime (Reporting) CIK: 0002041627 (see all company filings)

Type: 3 | Act: 34 | File No.: 033-80623 | Film No.: 241397261